Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T-Cell Lymphoma: An Open-Label Phase 2 Study (Gxplore-002)

Yuankai Shi, Jianqiu Wu, Zhen Wang, Liling Zhang, Zhao Wang, Mingzhi Zhang, Hong Cen, Zhigang Peng, Yufu Li, Lei Fan, Ye Guo, Liping Ma, Jie Cui, Yuhuan Gao, Haiyan Yang, Hongyu Zhang, Lin Wang, Weihua Zhang, Huilai Zhang, Liping Xie, Ming Jiang, Hui Zhou, Yue-Rong Shuang, Hang Su, Xiaoyan Ke, Chuan Jin, Xin Du, Li Liu, Yaming Xi, Zheng Ge, Ru Feng, Yang Zhang, Shengyu Zhou, Fan Xie, Qian WangSSRN 2020 · DOI

BibTeX
@misc{shi2020efficacy,
  author = {Yuankai Shi and Jianqiu Wu and Zhen Wang and Liling Zhang and Zhao Wang and Mingzhi Zhang and Hong Cen and Zhigang Peng and Yufu Li and Lei Fan and Ye Guo and Liping Ma and Jie Cui and Yuhuan Gao and Haiyan Yang and Hongyu Zhang and Lin Wang and Weihua Zhang and Huilai Zhang and Liping Xie and Ming Jiang and Hui Zhou and Yue-Rong Shuang and Hang Su and Xiaoyan Ke and Chuan Jin and Xin Du and Li Liu and Yaming Xi and Zheng Ge and Ru Feng and Yang Zhang and Shengyu Zhou and Fan Xie and Qian Wang},
  title = {{Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T-Cell Lymphoma: An Open-Label Phase 2 Study (Gxplore-002)}},
  year = {2020},
  doi = {10.2139/ssrn.3677881},
  howpublished = {SSRN},
}

Loading related content...

Figure